The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO TAT 2022 | Pre-clinical data for novel EGFR inhibitor BDTX-1535
Matthew Lucas, PhD, Black Diamond Therapeutics, Cambridge, MA, explains pre-clinical data for the novel EGFR inhibitor BDTX-1535. This data was collected from mouse models of glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC). Dr Lucas discusses two key pre-clinical trials, and explains the rationale behind moving into Phase I trials of BDTX-1535 in patients who have intrinsic or acquired resistance to currently-approved EGFR inhibitors. This interview was conducted at the virtual European Society for Medical Oncology Targeted Anti-Cancer Therapies (ESMO TAT) Congress 2022.
